View All Blog Posts

The Latest: Southeast Asian Patients Benefit From COVID-19 Innovation

Since the beginning of the COVID-19 pandemic, biopharmaceutical companies have found innovative ways to combat the global health crisis through unprecedented collaboration and partnerships, strengthened intellectual property rights and advanced research and development (R&D) processes. Innovators responded quickly by leveraging decades of existing research and scientific knowledge and building a robust innovation ecosystem that have since lead to several approved COVID-19 vaccines and treatments. As distribution continues to ramp up, patients throughout Southeast Asia are feeling the benefits of this biopharmaceutical investment and innovation.

Here is a closer look at some of the impact these innovations have had on people throughout Southeast Asia:

  • Pfizer’s partnership with BioNTech resulted in a COVID-19 vaccine that utilizes mRNA technology and has an efficacy rate of 95% after two doses. The vaccine has been approved for use by regulatory authorities in Singapore, Malaysia and the Philippines. As of mid-May 2021, more than 8 million Singaporeans have been inoculated with at least the first dose of an mRNA COVID-19 vaccine. In May 2021, BioNTech announced it will set up its Southeast Asia headquarters in Singapore, and will build a manufacturing facility in the city-state to produce “several hundreds of millions” of mRNA-based vaccine doses a year.
  • The AstraZeneca and Oxford University collaboration developed a non-replicating viral vector COVID-19 vaccine that yielded a 70% efficacy rate after two doses. Regulatory authorities in Thailand, Indonesia, Malaysia, Vietnam and the Philippines have endorsed the vaccine for emergency use and signed several agreements with the company to acquire millions of doses in 2021.
  • Scientists at Gilead leveraged pre-existing research to further develop remdesivir as a treatment indicated for use in severely ill COVID-19 patients. Health authorities in Singapore have conditionally approved remdesivir, which minimizes COVID-19 symptoms by interrupting the production of the virus and preventing the virus from multiplying.

These innovative collaborations and discoveries have already made a positive impact on the health of those in Southeast Asia. Policymakers in the region must continue to strengthen intellectual property rights so biopharmaceutical companies can continue to innovate and support broad patient access.

Recent Blog Posts

COVID-19 Shows the Essential Role of Ongoing Health Care Innovation

Great progress had been made in the fight against COVID-19. To date, 32.9% of the world’s population is at least partially vaccinated. Still, the global community has a long way to go before everyone is protected. Continuing to prioritize and support innovation to identify effective treatments, vaccines or boosters, and furthering our understanding of variants, remains critical to the global response.

Policy Solutions Can Help Innovative Cancer Treatments Reach SEA Patients

Breakthrough treatments and increased access to health care are helping people across Southeast Asia live longer than ever before. While the COVID-19 pandemic has brought new attention and respect for innovative treatments and medicines, more needs to be done to deploy novel therapeutics to combat longstanding challenges. For example, in 2016, the World Health Organization (WHO) declared non-communicable diseases (NCDs) – including cancer, diabetes, chronic respiratory conditions and cardiovascular diseases – the leading cause of death in Southeast Asia.